Form 4 for ONC BeOne Medicines Ltd.
Accepted 2026-06-10 17:23:57 ET · period of report 2026-06-08 · accession 0001739452-26-000005 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2026-06-10 17:23 | 2026-06-08 | ONC | Wu Xiaobin | Pres, COO | S - Sale | $269.37 | -1,484 | 0 | -100% | -$399.7K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | American Depositary Shares | 2026-06-08 | S | D | 1,444 | $269.33 | 40 | D | — | — | (F2) Each American Depositary Share represents 13 Ordinary Shares. (F3) The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 5, 2024, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control. (F4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $268.88 to $269.75, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. |
| 2 | Common | American Depositary Shares | 2026-06-08 | S | D | 40 | $270.55 | 0 | D | — | — | (F2) Each American Depositary Share represents 13 Ordinary Shares. (F3) The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 5, 2024, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control. |